Erdafitinib is an FDA approved drug for treating BLCA with FGFR3 mutation and an early clinical study showed that AMG 510 is a potential candidate for treating tumors with KRAS mutations30. Here, FGFR3 is linked to bladder transitional cell carcinoma.